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With the aim of improving the available drugs for the treatment of Chagas disease, individual enantiomers of nifurtimox were
characterized. The results indicate that the enantiomers are equivalent in their in vitro activity against a panel of Trypanosoma
cruzi strains; in vivo efficacy in a murine model of Chagas disease; in vitro toxicity and absorption, distribution, metabolism,
and excretion characteristics; and in vivo pharmacokinetic properties. There is unlikely to be any therapeutic benefit of an indi-
vidual nifurtimox enantiomer over the racemic mixture.
Nifurtimox is one of only two drugs currently registered for thetreatment of Chagas disease caused by the parasite Trypano-
soma cruzi. While nifurtimox is effective when treatment is initi-
ated during the acute stage of infection, its effectiveness in treating
the chronic stage of infection is highly variable (1). Treatment
with nifurtimox is associated with a high incidence of severe side
effects, and as a result, the related nitroheterocycle benznidazole is
currently the drug of choice for the treatment of Chagas disease. In
vivo, different strains of T. cruzi have been reported to exhibit
differing susceptibilities to nifurtimox, which may contribute to
variations in its effectiveness (2, 3).
Nifurtimox, a 5-nitrofuran that undergoes nitroreduction to
form the active species, is marketed as a racemate (Lampit); how-
ever, information regarding the biological activity and toxicolog-
ical and pharmacokinetic properties of the individual nifurtimox
enantiomers is not available in the scientific literature. With the
aim of improving the currently available chemotherapeutic op-
tions for treating Chagas disease, we characterized the individual
nifurtimox enantiomers for their antitrypanosomal activity
against a panel of T. cruzi strains and clones in vitro and assessed
their efficacy in a murine model of acute Chagas disease. We also
determined the in vitro toxicity profile and in vitro and in vivo
pharmacokinetic properties of each enantiomer relative to those
of the racemic mixture.
Nifurtimox racemate was synthesized by Epichem Pty. Ltd.,
Perth, Australia. Following separation of the enantiomers by su-
percritical fluid chromatography and recrystallization, their abso-
lute structurewas determined byX-ray diffraction (WuXiAppTec
Co., Ltd., Shanghai, China). The R and S enantiomers were as-
sessed against a panel of seven T. cruzi strains and clones, each a
member of a distinct lineage or discrete typing unit (Table 1.).
Mammalian and T. cruzi cultures and antiparasitic activity assays
were conducted as described previously (4). Briefly, T. cruzi-in-
fected U2OS monolayers were treated with benznidazole (con-
trol), a nifurtimox racemic mixture, or the individual enantiom-
ers for 72 h (DM28c) or 96 h (remaining clones and strains), and
the concentration resulting in 50% inhibition of parasite growth
(50% effective concentration [EC50]) relative to nontreated, in-
fected controls was determined. The EC50s of the racemate and
each of the enantiomers were in the low micromolar (benznida-
zole) to submicromolar (nifurtimox) range, with no significant
difference in potency between the enantiomers against the strains
and clones tested. A first estimation of cytotoxicity was done by
looking at the compound’s selectivity toward the parasite; it was
measured against the host cells, the human cell line U2OS, by
calculating the CC50, the ratio of (i) the average number of cells in
compound-treated, infected wells to (ii) the average number of
cells in nontreated (mock), infected negative controls. We found
that differences between the CC50s of the enantiomers were not
significant when the same strain or clone was considered (Table
1). Cytotoxicity assessment in the noninfected rat skeletal myo-
blast L6 cell line did not show any difference between the enan-
tiomers either.
In vivo efficacy was assessed as previously described (5), by
using amurine model of acute Chagas disease with approval from
the Animal Ethics Committee of Murdoch University. Female
Swiss mice (8 weeks old, n 5 per group) were infected intraperi-
toneally with 50,000 trypomastigotes (Tulahuen strain), and drug
treatment commenced on day 8 postinfection. Nifurtimox race-
mate or each individual enantiomer was administered by oral ga-
vage (100 mg/kg) once a day for 20 days. At the end of the 20-day
dosing period, 5 out of 5 mice in the nifurtimox racemate group
had undetectable levels of parasites in their blood as determined
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microscopically, compared to 4 out of 5 and 5 out of 5 in theR and
S enantiomer groups, respectively. To assess potential cures, the
parasitemia-negative animals in each group underwent up to
three rounds of immunosuppression with cyclophosphamide (50
mg/kg administered intraperitoneally once daily for 4 days, fol-
lowed by 3 days of rest); at the end of the immunosuppression
phase, a rebound of parasitemia was observed in all of the animals,
indicating that there were no complete cures when using this
model.
In vitro toxicity tests included inhibition of the human ether-à-
go-go-related gene (hERG) potassium channel and mutagenic po-
tential. For the hERG inhibition assay, an automated patch clamp
method (QPatchHTX; WuXi AppTec Co., Ltd., Shanghai, China)
was used and indicated that neither of the enantiomers exhibited
detectable inhibition of the channel (50% inhibitory concentra-
tion [IC50]  30 M). A mini-Ames assay (WuXi AppTec Ltd.,
Suzhou, China) using Salmonella enterica serovar Typhimurium
strains TA98 and TA100 in the presence or absence of exogenous
metabolic activation (Aroclor 1254-induced rat liver S9 mix)
turned out positive for each enantiomer (2-fold increase in the
mean number of revertant colonies); a similar increase in the
number of revertants per plate (reverse mutations at the selected
loci of the two tester strains) in the absence or presence of S9
activation was exhibited by each enantiomer.
Physicochemical and metabolic stability properties and CYP
inhibition were assessed as described previously (5). Both enan-
tiomers exhibited good aqueous solubility (50 to 100 g/ml) and
moderate lipophilicity (a distribution constant [log DpH 7.4] of
2.1) and were metabolically stable in the presence of human he-
patic microsomes (in vitro intrinsic clearance of7l/min/mg of
protein). The enantiomers both showed minimal inhibition of
cytochrome P450 3A4, with an IC50 of20M(data not shown).
The in vivo pharmacokinetic properties of (R)- and (S)-nifur-
timox were investigated in male Sprague-Dawley rats using pro-
tocols approved by the Monash Institute of Pharmaceutical
Sciences Animal Ethics Committee and in accordance with pro-
cedures outlined in the Australian Code of Practice for the Care
and Use of Animals for Scientific Purposes. Each enantiomer was
administered intravenously (i.v.) by constant-rate infusion (3mg/
kg) over 10 min into a catheter surgically inserted into the jugular
vein under isoflurane anesthesia. Oral doses (10 mg/kg) were ad-
ministered as an aqueous suspension by oral gavage. Blood sam-
ples were collected for up to 24 h postdose and analyzed by liquid
chromatography-mass spectrometry. Following i.v. administra-
tion, plasma (R)- and (S)-nifurtimox concentrations rapidly de-
clined to levels below the analytical lower limit of quantitation;
however, within the first 6 h, there was no discernible difference in
i.v. exposure between the two enantiomers. Similarly, after oral
administration, there was no substantial difference between the
profiles of (R)- and (S)-nifurtimox during the initial 5-h period,
and while concentrations of the R enantiomer at later sample
times were greater than those of (S)-nifurtimox, there was no
major difference in the overall exposure of the two enantiomers
(Fig. 1).
In summary, these studies reveal no evidence of nifurtimox
enantiomer stereoselectivity in relation to in vitro anti-T. cruzi
activity against multiple strains and clones or in vivo in a murine
model of acute Chagas disease. For selected toxicity parameters,
TABLE 1 EC50s of nifurtimox racemate and its purified enantiomers against a T. cruzi strain and clone panel
Strain or clone DTU
Nifurtimox racemate R enantiomer S enantiomer
EC50 (M) CC50 (M)
a SIb EC50 (M) CC50 (M) SI EC50 (M) CC50 (M) SI
Dm28c I 3.41 111.6 32.7 4.00 104.0 26.0 3.32 101.0 30.4
Y II 1.00 161.6 161.6 0.65 167.4 257.5 0.69 143.2 207.5
ARMA13 cl1 III 0.91 68.5 75.3 0.78 54.8 70.3 0.71 67.2 94.6
ERA cl2 IV 0.58 124.4 214.4 0.75 136.8 182.4 0.42 108.3 257.9
92.80 cl2 V 0.33 79.5 240.9 0.35 79.7 227.7 0.28 75.7 270.4
Tulahuen VI 0.32 117.7 367.8 0.32 120.0 375.8 0.25 107.1 428.4
CL Brener VI 0.76 63.8 83.9 0.65 58.3 89.7 0.92 74.9 81.4
a CC50 was measured against the U2OS cell line as described in Materials and Methods.
b SI, selectivity index, defined as the CC50/EC50 ratio.
FIG 1 Plasma concentration-versus-time profiles of (R)- and (S)-nifurtimox
in male Sprague-Dawley rats following i.v. (3 mg/kg, panel A) or oral (10
mg/kg, panel B) administration. Data are shown for two individual animals
per compound per dose and route. (R)-Nifurtimox is represented by filled
symbols, and (S)-nifurtimox is represented by open symbols. The dashed line
in each panel represents the analytical lower limit of quantitation.
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both enantiomers exhibited no detectable inhibition of the hERG
potassium channel, and both were similarly positive in a mini-
Ames mutagenicity test. There was no detectable difference be-
tween the physicochemical, metabolic, or pharmacokinetic prop-
erties of the two enantiomers. The results suggest that there is
unlikely to be any therapeutic benefit in relation to safety or effi-
cacy of an individual nifurtimox enantiomer over the racemic
mixture.
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